Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.